New research on more than 2.5 million people provides the clearest genetic picture of fibromyalgia to date. The findings point in particular to the nervous system and neuronal mechanisms, but at the same time show why fibromyalgia can hardly be reduced to a single cause. Genetics, pain processing, small nerve fibers, autonomic regulation, inflammation, sleep and individual differences appear to be part of a larger biological system.
In short – what have the researchers found?
Fibromyalgia is a real long-term pain condition with a measurable genetic component.
The largest genetic study of fibromyalgia to date was published in Nature Medicine July 28, 2026. The researchers analyzed data from 2,563,755 people from eleven cohorts. Of these, 54,629 people had registered fibromyalgia.
The researchers identified 26 independent genetic risk areas.
However, the most interesting thing was not only the number of genetic findings. The analyzes showed that the genetic risk was particularly linked to brain tissue and neuronal cell types.
This gives strong support to the fact that the nervous system and the way the body processes sensory signals and pain are central to fibromyalgia.
But the research does not provide grounds for concluding that all people with fibromyalgia have exactly the same biological mechanism.
On the contrary, recent research points in the direction of significant biological heterogeneity.
In some people, central pain amplification can be dominant. In others, peripheral nerve involvement, autonomic disturbances, sleep problems, immunological mechanisms, migraine, gastrointestinal problems or other concurrent factors may be important parts of the picture.
That begs the question "what causes fibromyalgia?" less precise than the question:
Which biological mechanisms are most important in this person?
Why the new research received a lot of attention in Norway
On 13 August 2026, Dagens Medisin referred to the large genetic study as both "a breakthrough and a confirmation".
Pain professor Audun Stubhaug at the University of Oslo and Oslo University Hospital stated that the study points towards a pathophysiology or pain mechanism that may be relevant for a large proportion of people diagnosed with fibromyalgia.
Professor Silje Endresen Reme also highlighted a crucial point: the absence of tissue damage does not mean the absence of biology.
This is perhaps the most important practical lesson from the research.
For years, many people with fibromyalgia have experienced extensive pain and functional problems at the same time that X-rays, MRI, blood tests and other conventional examinations do not show damage commensurate with the symptoms.
Unfortunately, it has sometimes been interpreted as making the symptoms less real.
Modern pain research shows why this is a fallacy.
Pain is not the same as tissue damage
Pain is a biological experience that arises through complex processes in the nervous system.
Sensory nerve fibers record information from the body. The signals are further processed in the spinal cord, brainstem and brain, where they can be continuously amplified, attenuated, filtered and integrated into a context.
Therefore, there is no simple linear relationship between the amount of tissue damage and the amount of pain.
Helsenorge emphasizes that the experience of pain itself is formed through a number of processes in the brain, and that, among other things, nerve activity, experience, situation and the body's regulatory systems influence the experience. This applies to all forms of pain.
The fact that you do not see an injury on an MRI therefore does not mean that the nervous system functions identically to the nervous system of a person without pain.
Fibromyalgia is a significant Norwegian health problem
Fibromyalgia must also be seen in the larger context of long-term pain.
The Institute of Public Health states that approximately one in three adult Norwegians report long-term pain. Long-term pain is also the biggest cause of non-fatal health loss in Norway and contributes significantly to reduced quality of life, sickness absence and disability. Women are affected more often than men.
Fibromyalgia represents only one part of this big pain picture.
What is fibromyalgia?
Fibromyalgia is primarily characterized by widespread and long-lasting pain.
Common additional symptoms can be fatigue, sleep problems, non-restorative sleep, concentration and memory problems, headaches or migraines, increased sensitivity to various sensory impressions and gastrointestinal problems such as irritable bowel.
The symptom picture varies considerably between people.
Helsenorge describes fibromyalgia as a chronic pain condition in which long-lasting pain occurs in various parts of the body, often together with fatigue and concentration problems.
Nociplastic pain – an important concept
Modern pain medicine often distinguishes between nociceptive, neuropathic and nociplastic pain.
Nociceptive pain is associated with activation of pain receptors due to actual or threatened tissue damage.
Neuropathic pain occurs as a result of disease or damage to the somatosensory nervous system.
Nociplastic pain describes pain related to altered nociception that cannot be fully explained by nociceptive or neuropathic mechanisms.
The International Association for the Study of Pain uses fibromyalgia as an important example of a nociplastic pain condition.
This does not mean that the pain is less physical.
This means that the actual regulation and processing of pain signals may have changed.
Central sensitization – the nervous system may become more responsive
Central sensitization is a neurophysiological phenomenon where nociceptive systems in the central nervous system develop an increased response.
In practice, it can contribute to hyperalgesia, where a painful stimulus is experienced stronger than expected, and allodynia, where stimuli that normally do not hurt can be experienced as painful.
Fibromyalgia is often associated with such mechanisms.
But it is important not to make central sensitization a universal explanation for the entire disease picture.
There is no single clinical test that measures the "amount of central sensitization" in a person and diagnoses fibromyalgia.
What does brain research show?
A systematic review published in European Journal of Pain in 2026 analyzed 91 neuroimaging studies of fibromyalgia.
The researchers did not find one specific MRI signature that could be used as a diagnostic biomarker.
The most consistent findings were instead related to distributed networks for pain processing and pain modulation.
Task-fMRI studies particularly showed signs of increased response in nociceptive networks and weaker or altered downward pain regulation.
It supports the idea that fibromyalgia is not necessarily about one fault in one particular part of the brain.
It might be more useful to think about network.
The largest genetic study to date
The Nature Medicine study represents a significant methodological leap.
It included more than 2.56 million people and identified 26 areas of risk associated with fibromyalgia.
A genomic region is not the same as a "fibromyalgia gene".
GWAS studies analyze millions of genetic variations and investigate whether certain variants occur slightly more often in people with a particular trait or diagnosis.
The effect of the individual variant is usually small.
Fibromyalgia therefore appears as a polygenic condition, where many genetic variations probably contribute small risk contributions.
Genetics is not destiny
It is important to understand what genetic risk means.
A person is not programmed for fibromyalgia just because certain risk variants exist.
Genetic factors work together with development, sex, hormones, environment, disease, sleep, physical stress, life events and other biological and social conditions.
The genetic study also showed that a polygenic risk score had limited ability to distinguish people with fibromyalgia from people without the diagnosis.
It therefore exists no clinically validated genetic test that diagnoses fibromyalgia.
Two major genetic studies were published on the same day
A particularly interesting detail from 2026 is that another large genetic fibromyalgia study was published in Nature Communications on the same day, July 28.
This analysis included 85,139 fibromyalgia cases and 1,642,433 control subjects.
The researchers found strong genetic links between fibromyalgia and chronic pain, PTSD and depression. They also found connections to immune- and autoimmune-related traits and several neuronal mechanisms.
The second study is important because it shows that genetic research does not support a single explanation.
Fibromyalgia appears to be at the intersection of several biological systems.
Genetic correlation is not the same as causation
Among other things, the Nature Communications study found a genetic correlation of approximately 0.80 with chronic pain, 0.72 with PTSD and 0.69 with depression in the European analysis.
Such numbers must be interpreted correctly.
A genetic correlation of 0.72 with PTSD does not mean that PTSD causes 72 percent of fibromyalgia cases.
This means that some genetic variants statistically overlap between the traits.
Such overlaps can occur for several reasons, including shared biological mechanisms and pleiotropy.
Is fibromyalgia an autoimmune disease?
There is insufficient documentation to classify fibromyalgia in general as a classic autoimmune disease.
At the same time, there are interesting immunological findings.
Experimental research has shown, among other things, that IgG antibodies from some people with fibromyalgia can transfer increased pain sensitivity to mice.
This is biologically interesting because it opens up the possibility that antibody or neuroimmune mechanisms may be relevant in certain subgroups.
But mouse experiments do not document that all people with fibromyalgia have an autoimmune disease.
There is also no established fibromyalgia-specific autoantibody test that is routinely used in diagnostics.
Inflammation – interesting but not a universal explanation
A systematic review and meta-analysis published in July 2026 examined inflammatory biomarkers in people with fibromyalgia.
Eighteen studies with a total of 1,605 participants were included.
The researchers found at group level a moderate increase in highly sensitive CRP, hsCRP. IL-6, IFN-γ and hair cortisol did not show correspondingly significant differences in the quantitative analysis.
At the same time, the studies were heterogeneous and the methodological quality moderate.
This means that low-grade inflammation may be relevant in some people, but that hsCRP is not a diagnostic test for fibromyalgia.
Inflammatory markers are also affected by a wide range of conditions, including body weight, infections, physical activity, sleep, smoking and other diseases.
Small nerve fibers – the peripheral nervous system enters the picture
Another area of research that has received increasing attention is small fiber pathology.
Small sensory nerve fibers contribute to, among other things, pain, temperature and autonomic signaling.
Several studies have found reduced small fiber density or other signs of small fiber pathology in a significant subset of people with fibromyalgia.
This does not mean that fibromyalgia and small fiber neuropathy are identical diagnoses.
But the findings challenge an overly simple model where everything is explained exclusively through the central nervous system.
The autonomic nervous system
Many people with fibromyalgia report symptoms that may involve autonomic regulation: palpitations, altered temperature sensitivity, sweating, dizziness, gastrointestinal problems, sleep problems, and reduced tolerance to exercise.
A systematic review from 2025 found that reduced resting HRV and altered autonomic response patterns have been reported repeatedly in people with fibromyalgia.
However, HRV is not a diagnostic test for fibromyalgia.
Heart rate variability is affected by, among other things, age, physical condition, sleep, alcohol, illness, medicines, measurement method and time of day.
HRV may therefore be most interesting as trend value over time when used in a broader context.
Gut–brain–nervous system
Fibromyalgia often occurs together with irritable bowel syndrome.
This makes the connection between the gut, nervous system and immune function interesting in terms of research.
The gut contains an extensive enteric nervous system that communicates with the brain and spinal cord through, among other things, vagal, spinal, hormonal and immunological signaling pathways.
It is therefore biologically plausible that changes in the gut environment can affect symptoms in some people.
But this is very different from claiming that fibromyalgia generally "starts in the gut."
There is no documentation for one universal intestinal cause.
Sleep is part of pain biology
Non-restorative sleep is one of the most common symptoms of fibromyalgia.
Sleep and pain mutually influence each other.
Poor sleep can increase pain sensitivity, affect emotional regulation, reduce concentration and alter autonomic function. Pain can also make it more difficult to achieve deep and continuous sleep.
It may therefore be relevant to investigate factors such as sleep apnoea, restless legs, circadian rhythm, alcohol, caffeine, medicines and sleep environment in people with significant sleep problems.
For more on sleep and physiological regulation, you can read Uno Vita's specialist material on stress and recovery:
Holistic treatment of chronic stress
Stress is physiology - but not the whole explanation
Long-term stress affects autonomic nervous systems, hormones, sleep, immune signaling, muscle tone and pain regulation.
Thus, stress can be a symptom-intensifying factor.
But this does not mean that fibromyalgia is only caused by stress or wrong thought patterns.
The important distinction is between influencing factors and one single reason.
People with an identical diagnosis can have very different combinations of biological vulnerability, medical history, sleep problems, physical strain and psychosocial conditions.
The diagnosis is still clinical
As of August 2026, there is no single blood test, genetic test or MRI examination that alone can diagnose fibromyalgia.
The diagnosis is still based on medical history, symptoms and clinical assessment.
Genetic research is changing the understanding of the disease faster than it is changing practical diagnostics.
This is important because it also means that new symptoms should not automatically be explained by an existing fibromyalgia diagnosis.
Other or concurrent diseases must be assessed when clinically relevant.
The future may be biological subgroups
One of the most interesting consequences of current research is the possibility that "fibromyalgia" may in the future be divided into biological subgroups.
Two people may meet the same diagnostic criteria, yet have different dominant mechanisms.
In one person, altered central pain processing may dominate.
In another, autonomic symptoms may be particularly prominent.
In a third, small fiber pathology may be relevant.
A fourth may have significant migraine, IBS or immunological comorbidity.
This may explain why one treatment strategy never works equally well for everyone.
Future fibromyalgia research may therefore move from a general diagnosis to phenotyping and mechanism-based treatment.
What is best documented today?
Although the biology is increasingly better understood, there is still no simple cure.
Norwegian and international guidelines emphasize individually adapted, multimodal follow-up.
Physical activity is among the best researched non-pharmacological interventions.
A meta-analysis published in 2026 included 22 studies with 1,235 participants and found small but statistically significant improvements in, among other things, pain, fatigue, sleep, physical function and psychological symptoms after strength training. A lower training dose and moderate intensity could be sufficient.
Another network meta-analysis of 20 randomized trials found positive results for several forms of aerobic and movement-based activity.
The most important practical principle is individual dosing.
"Exercise more" is not a treatment plan.
Photobiomodulation and red/near-infrared light
Photobiomodulation, PBM, is particularly interesting because a systematic review published in June 2026 directly examined PBM in fibromyalgia.
The review found seven randomized controlled trials.
Several reported short-term improvements in pain and quality of life. Certain studies also reported positive changes in sleep and psychological well-being.
The researchers described PBM as a promising adjunctive approach, but at the same time emphasized considerable variation in doses, wavelengths, treatment sites and study design.
This means that PBM should not currently be presented as an established cure or universal treatment for fibromyalgia.
However, there is a growing research base that makes the technology interesting for further studies.
Uno Vita offers a range of systems for red and near-infrared light intended for general photobiomodulation, recovery and well-being.
See Uno Vita's selection of red light and NIR technology
The products' approved area of use and product information apply independently of the research discussed in this article.
PEMF – pulsed electromagnetic fields
PEMF is another area of biophysical research.
Pulsating electromagnetic fields can affect biological tissue through time-varying electromagnetic fields, and several forms of PEMF are used or investigated within rehabilitation, musculoskeletal issues and recovery.
Fibromyalgia research is, however, significantly less extensive than what you sometimes get the impression of online.
There are positive pilot studies, but also methodological limitations, small samples and different protocols.
PEMF should therefore not be referred to as one of the "best documented treatments" for fibromyalgia.
A more precise conclusion is that technology is an interesting research and wellness area where fibromyalgia documentation is currently limited.
Read more about Uno Vita's professional PEMF systems
Uno Vita's current system is described as a professional system for physical stimulation, muscle comfort, recovery and well-being, not as a specific treatment for fibromyalgia.
The vagus nerve and non-invasive neuromodulation
The autonomic nervous system and the vagus nerve have also become current areas of research.
A systematic review published at the turn of the year 2025–2026 identified six studies or protocols related to vagus stimulation and fibromyalgia.
The results were assessed as promising, but small study groups, varying stimulation techniques and different methodologies limit how strong conclusions can be drawn.
This is a classic example of the difference between promising research and established treatment.
Nutrition and dietary supplements
Nutrients such as magnesium, vitamin D, B vitamins, omega-3 and coenzyme Q10 are biologically relevant for normal energy metabolism, nerve function, muscle function or other physiological processes.
This does not mean that all people with fibromyalgia need the same supplements.
Nor has one universal "fibromyalgia protocol" been documented.
A more rational strategy is to ensure a varied and nutrient-dense diet and assess actual deficiencies or special needs when relevant.
Dietary supplements should not be used as a substitute for necessary medical assessment.
See Uno Vita's category for dietary supplements
Uno Vita's biophysical perspective
Over many years, Uno Vita has worked with biophysics, photobiomodulation, PEMF, autonomous regulation, restitution and other health technology.
A basic principle is that the body does not consist of isolated systems.
Cells function through electrochemical gradients.
Nerve cells communicate through changes in membrane potential.
The heart generates electrical signals.
Muscle function depends on electrochemical activation.
Mitochondria maintain proton gradients that are fundamental to ATP production.
This is established physiology.
At the same time, it is important to separate this biological reality from the claim that any technology that uses electromagnetic fields, electricity, light or frequency automatically has a clinically documented effect against fibromyalgia.
Biophysical plausibility is not the same as clinical efficacy.
For Uno Vita, this difference is important.
Holistic health should be more scientifically precise, not less.
Measurement can be useful - but the measurement must be understood correctly
In an integrated follow-up course, certain functional measurements can provide additional information.
HRV can be used to follow autonomic response and recovery trends.
Bioimpedance can, among other things, be used to assess body composition and certain electrical tissue properties.
Such measurements do not diagnose fibromyalgia.
They can possibly be used to follow general physiological parameters over time.
There is a crucial distinction.
Measure – change – evaluate
With complex symptom patterns, another problem often arises: too many measures are started at the same time.
If a person changes their diet, starts taking more food supplements, starts exercise, PBM, PEMF, sleep protocol and several other measures in the same week, it becomes almost impossible to know what actually influenced the result.
A more systematic strategy is to establish a starting situation and then make a limited number of changes at a time.
Relevant measures can be pain intensity, sleep quality, function, activity level, number of symptom-heavy days, strength or tolerance for everyday activities.
This makes self-monitoring more informative and reduces the risk of interpreting random variations as a treatment effect.
Fibromyalgia and ME/CFS are not the same
Fibromyalgia and ME/CFS can share symptoms such as pain, fatigue, sleep problems and cognitive difficulties.
They are nevertheless different diagnoses.
Post-exertional malaise, PEM, is particularly central in ME/CFS and can make the exercise response different.
Standardized exercise advice should therefore not be uncritically transferred from fibromyalgia to people with clear PEM.
Frequently asked questions about fibromyalgia
Is fibromyalgia a real biological condition?
Yes. New genetic research shows a measurable polygenic component, and both genetics and neuroimaging support the importance of neuronal mechanisms. The fact that normal examinations do not show tissue damage does not make the symptoms any less biological.
Is fibromyalgia a disease of the brain?
It is more precise to say that the nervous system and altered pain processing are central. Genetic signals are strong in brain tissue and neuronal cell types, but peripheral nerve biology, autonomic systems and other mechanisms may also be relevant.
Is there a fibromyalgia gene?
No. Fibromyalgia is polygenic. Many genetic variants contribute with small effects.
Can fibromyalgia be diagnosed with a genetic test?
No. Today's polygenic risk models are not precise enough for clinical diagnostics.
Can MRI show fibromyalgia?
Not in a way that diagnoses individuals. The research finds group differences in distributed brain networks, but no established diagnostic MRI signature.
Is fibromyalgia autoimmune?
It has not been documented that fibromyalgia is generally a classic autoimmune disease. Immunological mechanisms are nevertheless interesting research tracks and may prove to be relevant for certain subgroups.
Is inflammation involved?
There is evidence of low-grade inflammatory differences at the group level, but the research is heterogeneous and does not provide a specific diagnostic inflammatory profile.
Can physical activity help?
At group level, systematic reviews show small to moderate improvements in several symptoms and functional measures. Load should be adapted individually.
What about red light therapy?
PBM has promising short-term data from small randomized trials, but protocols vary considerably and more standardized research is needed.
What about PEMF?
PEMF is biologically and research-wise interesting, but the direct clinical data base for fibromyalgia is still limited and cannot be equated with established treatment.
Can fibromyalgia be cured?
There is currently no universal cure. The aim of follow-up is usually reduced symptom burden, better function, better sleep, greater coping and a higher quality of life.
The real paradigm shift
The most important change in 2026 may not be that scientists have found 26 genetic regions.
The most important change is the question itself.
In the past, the debate has often been:
"Is fibromyalgia really biological?"
That question is becoming less and less relevant.
Genetics, neuroimaging, pain physiology, small fiber research, autonomic research and immunological studies already show that biological systems are involved.
The more interesting question is:
"What combination of biological mechanisms creates and maintains the symptoms in different groups of people?"
There probably lies the next big phase in fibromyalgia research.
Conclusion
2026 marks an important step forward in the understanding of fibromyalgia.
The largest genetic study to date shows a clear polygenic component and strong links to neuronal biology.
Another large genetic study published on the same day also shows extensive connections between fibromyalgia, pain, neuronal mechanisms, psychological traits and immune-related genetics.
Neuroimaging research shows distributed changes in pain processing rather than a single biomarker.
The inflammation research points to possible low-grade differences in some, but not one universal inflammatory profile.
Autonomous research and small fiber studies show further biological variation.
The overall picture is therefore not a new simple explanation.
There is a far more interesting picture:
Fibromyalgia appears as a biologically heterogeneous, long-term pain condition where neuronal pain processing is central, but where several biological systems can contribute differently in different people.
It fits well with Uno Vita's system-oriented philosophy.
The body must be understood as an interaction between the nervous system, metabolism, sleep, activity, immune function, psychosocial stress, autonomic regulation and the environment.
But a holistic perspective does not mean that all explanations are equally likely or that all treatments work.
It means combining curiosity with critical assessment of the documentation.
Completeness does not mean that everything works. Wholeness means seeing the connections without losing scientific precision.
Related content at Uno Vita
Holistic treatment of chronic stress
Uno Vita red light and NIR technology
Uno Vita High Intensity PEMF – EMTSF PRO 2S N
Mood and stress - support for calm, balance and mental clarity
About Uno Vita's editorial staff
Uno Vita AS in Moss conveys knowledge about integrated health, nutrition, biophysics, lifestyle, recovery and modern health technology. The aim is to make advanced research comprehensible and practically relevant, while clearly distinguishing between established knowledge, promising research and hypotheses that have not yet been sufficiently documented.
Uno Vita believes that a modern understanding of health can accommodate both conventional biomedicine, lifestyle, physiology and biophysics without scientific requirements for documentation being set aside.
Freedom of expression, research and professional openness
Science is developed through criticism, open discussion, replication and the opportunity to challenge existing explanatory models when new data is available.
Uno Vita supports the free dissemination and discussion of publicly available research within the framework of freedom of expression and applicable legislation.
A hypothesis should nevertheless be presented as a hypothesis. A promising research result should not be presented as an established treatment until the documentation supports this.
Medical disclaimer
This article has been prepared for general information and professional dissemination and is not intended as individual medical advice, diagnostics or treatment.
Fibromyalgia and long-term pain can occur together with other diseases. New, serious or significantly changed symptoms should be assessed by a doctor or other qualified healthcare personnel.
People who use medicines, are pregnant or breast-feeding, have a serious illness or are considering major changes in treatment, diet, dietary supplements or use of health technology should discuss this with the relevant health personnel.
Products and technologies mentioned in the article should not be understood as approved treatment of fibromyalgia unless this is expressly stated in the individual product's approved purpose.
Scientific references
- Kerrebijn I, Bjornsdottir G, Arbabi K, et al. The genetic architecture of fibromyalgia across 2.5 million individuals. Nature Medicine. 2026;32:3060–3070. DOI: 10.1038/s41591-026-04492-6.
- Bright U, Beck S, Levey DF, et al. The genetics of fibromyalgia and its relationships to psychiatric and medical traits. Nature Communications. 2026;17:6248. DOI: 10.1038/s41467-026-75256-6.
- Today's Medicine. New major study of fibromyalgia: - Both a breakthrough and a confirmation. Published August 13, 2026.
- Healthcare. Fibromyalgia – long-term pain.
- The Institute of Public Health. Long-term pain in Norway.
- Healthcare. Coping with long-term pain.
- Kosek E. The concept of nociplastic pain – where to from here? Pain. 2024.
- Flutt FAD, Cortez JPM, Ramos LR, et al. Structural and Functional Neuroimaging Findings in Fibromyalgia: A Systematic Review. European Journal of Pain. 2026;30(6). DOI: 10.1002/ejp.70331.
- Fernández-Rodríguez FJ, Delgado-Pérez E, Salgado-Ortiz CS, et al. Inflammatory biomarker alterations in patients with fibromyalgia: a systematic review and meta-analysis. BMC Rheumatology. 2026. DOI: 10.1186/s41927-026-00677-1.
- Marshall A, Elshafei M, Preston FG, et al. Small Fiber Pathology in Fibromyalgia: A Review. Pain and Therapy. 2025;14:461–478.
- Di Bari A, Demo G, Patron E. Unraveling the relationship between anxiety, autonomic nervous system dysfunction and fibromyalgia: a systematic review. Clinical and Experimental Rheumatology. 2025;43:1136–1145.
- Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. Journal of Clinical Investigation. 2021;131.
- Swathi GA, Maiya GA, Shetty S, et al. Effect of photobiomodulation on pain and quality of life in fibromyalgia syndrome: a systematic review. Lasers in Medical Science. 2026;41:125. DOI: 10.1007/s10103-026-04930-4.
- Ferreira LMA, Oliveira ABC, Mendes JJB, et al. Photobiomodulation in chronic pain: a systematic review of randomized clinical trials. Frontiers in Integrative Neuroscience. 2026;20:1717372.
- Rech A, Casagranda E, Radaelli R, et al. A systematic review and meta-analysis on the benefits of resistance exercise in patients with fibromyalgia. Journal of Bodywork and Movement Therapies. 2026;47:636–645.
- Yuan W, Yan P, Gao F, et al. Effectiveness of aerobic exercise in fibromyalgia: A systematic review and network meta-analysis. Complementary Therapies in Medicine. 2026;98:103352.
- Perin JP, Pastora-Sesín C, Kang S, et al. Potential of Vagus Nerve Stimulation to Modulate Fibromyalgia's Network Physiology: A Systematic Review. Journal of Functional Morphology and Kinesiology. 2026;11(1):15.
- Iannuccelli C, Favretti M, Dolcini G, et al. Fibromyalgia: one year in review 2025. Clinical and Experimental Rheumatology. 2025;43(6):957–969.
